Bionet Corp.

As of June 30, 2026, Bionet Corp. carries a market capitalization of 3.37B, placing it among publicly traded companies globally. Its enterprise value stands at 3.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bionet Corp.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Bionet Corp. has 49.79M shares outstanding.

As of June 30, 2026, Bionet Corp. trades at a trailing price-to-earnings ratio of 59.82. The price-to-sales ratio is 2.64, and the price-to-book ratio stands at 2.75.

As of June 30, 2026, Bionet Corp. trades at an EV/EBITDA multiple of 51.58 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Bionet Corp. trades at an EV/FCF ratio of 46.30, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.02B versus a market cap of 3.37B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bionet Corp. maintains a current ratio of 4.27, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.43, indicating elevated leverage, while an interest coverage ratio of 23.98 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bionet Corp. posted a return on equity (ROE) of 4.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.26, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 1.86, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.60, useful for judging operating efficiency across full business cycles. The company generates approximately 6.64M in revenue per employee across its workforce of 195.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.68 indicates how many times Bionet Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bionet Corp. recorded 13.10M in income tax expense. That works out to an effective tax rate of 61.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 21.46M, leaving 57.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bionet Corp.'s stock has declined approximately 40.61% over the past 52 weeks. The 50-day moving average sits at 59.63, while the 200-day moving average is 75.32.

Over the twelve months ended June 30, 2026, Bionet Corp. generated 1.29B in revenue and converted that into 57.18M in net income, yielding earnings per share of 0.17. EBITDA reached 58.62M, while operating income came in at -11.40M.

As of June 30, 2026, Bionet Corp. holds 1.46B in cash and equivalents against 141.63M in total debt, resulting in a net debt position of -95.80M. Total book value stands at 1.23B, with working capital of 1.47B providing operational flexibility.

Bionet Corp. produced 169.12M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -104.76M in capital expenditures, free cash flow totaled 64.36M - equivalent to 1.27 per share.

Over the twelve months ended June 30, 2026, Bionet Corp. posted a gross margin of 55.80, reflecting its pricing power and cost economics. The operating margin of -0.88 and net profit margin of 4.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.88, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bionet Corp. shareholders.

Bionet Corp.'s most recent stock split took place on September 19, 2024 with a 141:151 split ratio.

As of June 30, 2026, Bionet Corp. has an Altman Z-Score of 3.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.